Evidence map›Paper›PMID 41544065›Full record

ArticlePloS one2026

Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model.

Dylan M Lanser, Adam Turner, Noah Pacifici, Kiem Vu, Jamal Lewis, Angie Gelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dylan M LanserDepartment of Pharmacology, School of Medicine, University of California, Davis, California, United States of America.
Adam TurnerDepartment of Pharmacology, School of Medicine, University of California, Davis, California, United States of America.ORCID https://orcid.org/0009-0002-9392-014X
Noah PacificiDepartment of Biomedical Engineering, University of California, Davis, California, United States of America.
Kiem VuDepartment of Pharmacology, School of Medicine, University of California, Davis, California, United States of America.
Jamal LewisDepartment of Biomedical Engineering, University of California, Davis, California, United States of America.
Angie GelliDepartment of Pharmacology, School of Medicine, University of California, Davis, California, United States of America.ORCID https://orcid.org/0000-0003-3351-0683

Funding

Leveraging Engineering Approaches to understand Cryptococcal Vomocytosis from Immune CellsR35GM125012 · NIGMS · UNIVERSITY OF FLORIDA · PI Jamal S Lewis · 2017 to 2026
$3.2M
The molecular basis for the translocation of fungi from blood-to-brain.R01NS110800 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GELLI, ANGIE · 2020 to 2024
$2.3M
The role of a fungal metalloprotease in breaching the blood-brain barrierR21AI122329 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GELLI, ANGIE · 2016 to 2017
$432k
NIAID NIH HHS R21 AI122329NIGMS NIH HHS R35 GM125012NINDS NIH HHS R01 NS110800
6 · The paper itself

Abstract

Overcoming the blood-brain barrier to deliver therapeutics is a major hurdle in treating diseases of the central nervous system. We engineered 4-arm carboxyl terminated poly(D,L-lactide-co-glycolide) nanoparticles with the fungal metalloprotease Mpr1, an enzyme utilized by the neurotropic pathogen Cryptococcus neoformans (Cn) to cross the blood-brain barrier. Nanoparticles were prepared using a modified single emulsion solvent evaporation technique, and characterized in terms of shape, size, zeta potential, encapsulation efficiency, and toxicity to brain microvascular endothelial cells. Mpr1-functionalized nanoparticles had increased penetration over non-functionalized nanoparticles in an in vitro model of the blood-brain barrier. When encapsulating amphotericin B, a potent antifungal drug, Mpr1-functionalized nanoparticles reduced fungal burden in an in vitro model of neural cryptococcosis. Loaded nanoparticles also had an 8-fold lower minimum inhibitory concentration against Cn and Candida albicans (Ca) compared to unencapsulated amphotericin B. Results indicate that Mpr1-coating of polymeric nanoparticles is a promising strategy to enhance drug delivery to the brain.

Indexed as

Antifungal AgentsCryptococcosisCryptococcus neoformansLactic AcidMetalloproteasesNanoparticlesPolyglycolic AcidAmphotericin BAnimalsBlood-Brain BarrierCandida albicansEndothelial CellsHumansMicrobial Sensitivity TestsPolylactic Acid-Polyglycolic Acid CopolymerAmphotericin BAntifungal AgentsLactic AcidMetalloproteasesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymer

Identifiers

PMID41544065
PMCPMC12810805

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.